Literature DB >> 26284600

Diffusion MRI with Semi-Automated Segmentation Can Serve as a Restricted Predictive Biomarker of the Therapeutic Response of Liver Metastasis.

Renu M Stephen1, Abhinav K Jha2, Denise J Roe3, Theodore P Trouard4, Jean-Philippe Galons5, Matthew A Kupinski6, Georgette Frey7, Haiyan Cui7, Scott Squire5, Mark D Pagel8, Jeffrey J Rodriguez9, Robert J Gillies10, Alison T Stopeck7.   

Abstract

PURPOSE: To assess the value of semi-automated segmentation applied to diffusion MRI for predicting the therapeutic response of liver metastasis.
METHODS: Conventional diffusion weighted magnetic resonance imaging (MRI) was performed using b-values of 0, 150, 300 and 450s/mm(2) at baseline and days 4, 11 and 39 following initiation of a new chemotherapy regimen in a pilot study with 18 women with 37 liver metastases from primary breast cancer. A semi-automated segmentation approach was used to identify liver metastases. Linear regression analysis was used to assess the relationship between baseline values of the apparent diffusion coefficient (ADC) and change in tumor size by day 39.
RESULTS: A semi-automated segmentation scheme was critical for obtaining the most reliable ADC measurements. A statistically significant relationship between baseline ADC values and change in tumor size at day 39 was observed for minimally treated patients with metastatic liver lesions measuring 2-5cm in size (p=0.002), but not for heavily treated patients with the same tumor size range (p=0.29), or for tumors of smaller or larger sizes. ROC analysis identified a baseline threshold ADC value of 1.33μm(2)/ms as 75% sensitive and 83% specific for identifying non-responding metastases in minimally treated patients with 2-5cm liver lesions.
CONCLUSION: Quantitative imaging can substantially benefit from a semi-automated segmentation scheme. Quantitative diffusion MRI results can be predictive of therapeutic outcome in selected patients with liver metastases, but not for all liver metastases, and therefore should be considered to be a restricted biomarker.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Diffusion MRI; Liver imaging; Restricted biomarker

Mesh:

Substances:

Year:  2015        PMID: 26284600      PMCID: PMC4658325          DOI: 10.1016/j.mri.2015.08.006

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  36 in total

Review 1.  Basic principles of diffusion-weighted imaging.

Authors:  Roland Bammer
Journal:  Eur J Radiol       Date:  2003-03       Impact factor: 3.528

2.  Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.

Authors:  Kuei C Lee; Bradford A Moffat; Anne F Schott; Rachel Layman; Steven Ellingworth; Rebecca Juliar; Amjad P Khan; Mark Helvie; Charles R Meyer; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Image analysis using mathematical morphology.

Authors:  R M Haralick; S R Sternberg; X Zhuang
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1987-04       Impact factor: 6.226

Review 4.  Diffusion weighted imaging in the liver.

Authors:  Petra G Kele; Eric J van der Jagt
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

5.  Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients.

Authors:  Dow-Mu Koh; Erica Scurr; David Collins; Baris Kanber; Andrew Norman; Martin O Leach; Janet E Husband
Journal:  AJR Am J Roentgenol       Date:  2007-04       Impact factor: 3.959

6.  Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI.

Authors:  Dominique Jennings; B Nicholas Hatton; Jingyu Guo; Jean-Philippe Galons; Theodore P Trouard; Natarajan Raghunand; James Marshall; Robert J Gillies
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

7.  Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results.

Authors:  Yoshiko Hayashida; Toshitake Yakushiji; Kazuo Awai; Kazuhiro Katahira; Yoshiharu Nakayama; Osamu Shimomura; Mika Kitajima; Toshinori Hirai; Yasuyuki Yamashita; Hiroshi Mizuta
Journal:  Eur Radiol       Date:  2006-08-15       Impact factor: 5.315

8.  Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.

Authors:  Ada T W Ma; Brigette B Y Ma; Kenny I K Lei; Frankie K F Mo; Anthony T C Chan
Journal:  Hong Kong Med J       Date:  2010-06       Impact factor: 2.227

9.  Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging.

Authors:  Ying-Shi Sun; Xiao-Peng Zhang; Lei Tang; Jia-Fu Ji; Jin Gu; Yong Cai; Xiao-Yan Zhang
Journal:  Radiology       Date:  2009-12-17       Impact factor: 11.105

10.  Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck.

Authors:  Daniel A Hamstra; Kuei C Lee; Bradford A Moffat; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

View more
  5 in total

1.  No-gold-standard evaluation of image-acquisition methods using patient data.

Authors:  Abhinav K Jha; Eric Frey
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2017-03-10

2.  Practical no-gold-standard evaluation framework for quantitative imaging methods: application to lesion segmentation in positron emission tomography.

Authors:  Abhinav K Jha; Esther Mena; Brian Caffo; Saeed Ashrafinia; Arman Rahmim; Eric Frey; Rathan M Subramaniam
Journal:  J Med Imaging (Bellingham)       Date:  2017-03-03

3.  A maximum-likelihood method to estimate a single ADC value of lesions using diffusion MRI.

Authors:  Abhinav K Jha; Jeffrey J Rodríguez; Alison T Stopeck
Journal:  Magn Reson Med       Date:  2016-01-07       Impact factor: 4.668

4.  Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.

Authors:  Savannah C Partridge; Zheng Zhang; David C Newitt; Jessica E Gibbs; Thomas L Chenevert; Mark A Rosen; Patrick J Bolan; Helga S Marques; Justin Romanoff; Lisa Cimino; Bonnie N Joe; Heidi R Umphrey; Haydee Ojeda-Fournier; Basak Dogan; Karen Oh; Hiroyuki Abe; Jennifer S Drukteinis; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2018-09-04       Impact factor: 29.146

5.  A biomimetic tumor tissue phantom for validating diffusion-weighted MRI measurements.

Authors:  Damien J McHugh; Feng-Lei Zhou; Ian Wimpenny; Gowsihan Poologasundarampillai; Josephine H Naish; Penny L Hubbard Cristinacce; Geoffrey J M Parker
Journal:  Magn Reson Med       Date:  2017-11-20       Impact factor: 4.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.